摘要
目的通过对社区获得性肺炎病历报告的调查,分析比较4组方案的临床治疗效果;通过成本-效果分析方法,比较其经济性,并得出相对较优的治疗方案,从而指导临床合理用药。方法采用回顾性调查方法,收集九江地区2所三甲医院2010年10月至2012年8月间住院的社区获得性肺炎患者病例资料,从中筛选出符合本研究治疗方案的病例共181例,将其分成4组(A组:美洛西林钠/舒巴坦钠+阿奇霉素,B组:哌拉西林钠/舒巴坦钠+阿奇霉素,C组:哌拉西林钠/舒巴坦钠+左氧氟沙星,D组:美洛西林钠/舒巴坦钠+左氧氟沙星),对4组方案的治疗效果和成本-效果进行比较分析,比较各组治疗方案的优劣。结果 4组治疗方案的总有效率分别为58.49%、68.33%、83.87%、67.57%,经x2检验,差异无统计学意义(p=0.122);成本-效果比分别为28.93、40.12、26.32、22.34。结论单位效果的成本以D方案最为经济,值得临床推广应用。
ObjectiveThrough the investigation of the case report,the clinical treatment effects and normative medication of the four group programs were analyzed and compared,in order to guide reasonable medication in practice.Method Using the retrospective survey methodology,collecting the clinical data of hospitalized patients with community-acquired pneumonia in two three A-level hospitals of the Jiujiang area（Jiujiang First People＇s Hospital and Jiujiang University clinical medical school / Jiujiang University Hospital） from October 2010 to August 2012,and by filtering 181 cases in keeping with issue from it,divided them into 4 groups（A group： Mezlocillin sodium/Sulbactam sodium＋Azithromycin,B group： Piperacillin Sodium/Sulbactam Sodium＋Azithromycin,C group： Mezlocillin sodium/Sulbactam sodium＋Levofloxacin,D group： Piperacillin Sodium/Sulbactam Sodium ＋Levofloxacin）and carried on the cost-effectiveness method,and compared Pros and cons of each group treatment program.Result Total efficiency of the four groups were 58.49%,68.33%,83.87%,67.57%.Through test,the difference was not statistically significant（P = 0.122）;cost-effectiveness of them were 28.93,40.12,26.32,22.34.Conclusion From the economic perspective,the cost per unit effect of D program is the most economical program,which is worthy of clinical application.
出处
《九江学院学报（自然科学版）》
CAS
2013年第1期83-87,共5页
Journal of Jiujiang University：Natural Science Edition
基金
九江市科技局课题(编号九科字[2012]63号)成果之一
关键词
药物经济学
成本-效果分析
社区获得性肺炎
pharmacoeconomics
cost-effectiveness analysis
community acquired pneumonia
